CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
R-nuucell is developing a novel drug aimed at treating Triple Negative Breast Cancer, a type of cancer with limited treatment options. The drug targets the cytoskeleton of cancer cells to prevent their ability to invade and metastasize, addressing a critical clinical need.
R-nuucell is developing a new drug to treat Triple Negative Breast Cancer (TNBC) for which there is not any specific and efficient treatment in the market, making this disease an unmet clinical need.The aggressivity of TNBC is due to the easiness of its metastization expanding the cancer through the body inevitably leading to death.
So far, we gathered a set of results showing the antimetastatic potential of our new drug which mode of action would, conceptually, be able to eliminate the deadlies…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
